Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arcutis Biotherapeutics Inc.

15.01
-0.2600-1.70%
Post-market: 15.100.0900+0.60%19:59 EDT
Volume:1.43M
Turnover:21.38M
Market Cap:1.79B
PE:-14.43
High:15.30
Open:15.24
Low:14.70
Close:15.27
Loading ...

Press Release: Arcutis Announces Chief Financial Officer Transition

Dow Jones
·
11 Apr

Arcutis Biotherapeutics Price Target Maintained With a $20.00/Share by Needham

Dow Jones
·
09 Apr

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
05 Apr

Arcutis Biotherapeutics Price Target Maintained With a $20.00/Share by Needham

Dow Jones
·
03 Apr

Strategic Advantage and Market Confidence: Arcutis Biotherapeutics’ Extended Exclusivity and Buy Rating Amidst Competitive Risks

TIPRANKS
·
03 Apr

Why Arcutis Biotherapeutics Inc. (ARQT) Went Up On Wednesday?

Insider Monkey
·
03 Apr

Arcutis Biotherapeutics (ARQT) Receives a Buy from Mizuho Securities

TIPRANKS
·
03 Apr

BRIEF-Arcutis And Padagis Agree To Stay Patent Lawsuit

Reuters
·
03 Apr

BUZZ-Arcutis rises after halting patent dispute with Padagis

Reuters
·
03 Apr

Arcutis Agrees to Stay Patent Lawsuit Against Padagis

MT Newswires Live
·
03 Apr

Arcutis Biotherapeutics: Padagis to Report to Co Any FDA Correspondence About Anda for Their Generic Alternative to Zoryve Cream 0.3%

THOMSON REUTERS
·
03 Apr

Arcutis and Padagis Agree to Stay Patent Lawsuit

THOMSON REUTERS
·
03 Apr

How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85%

Zacks
·
28 Mar

Are Medical Stocks Lagging Cardinal Health (CAH) This Year?

Zacks
·
28 Mar

Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Eledon Pharmaceuticals (ELDN) and Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
25 Mar

ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age

CNW Group
·
17 Mar

Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), Labcorp Holdings (LH) and Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
17 Mar

Arcutis Biotherapeutics Is Maintained at Buy by Jefferies

Dow Jones
·
12 Mar

Arcutis Biotherapeutics price target raised to $19 from $16 at Jefferies

TIPRANKS
·
12 Mar

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 27% Share Price Surge Not Quite Adding Up

Simply Wall St.
·
09 Mar